FAQ

iodine-131-tositumomab

Known as: I 131 Monoclonal Antibody Anti-B1, tositumomab iodine i 131, Iodine I 131 Monoclonal Antibody Anti-B1 
A monoclonal antibody (tositumomab) that has been chemically changed by adding radioactive iodine, and that is used in the treatment of certain types… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1985-2018
05101519852018

Related topics

Related topics

6 relations

Broader (2)

Antineoplastic AgentsMonoclonal Antibodies

Narrower (1)

Bexxar
Human B-Lymphocyte Antigen CD20, humanTositumomab and Iodine I 131 Tositumomab Therapytositumomab

Related mentions per year

Related mentions per year

1947-2018
19401960198020002020
iodine-131-tositumomab
Monoclonal Antibodies
Antineoplastic Agents
Tositumomab and Iodine I 131 Tositumomab Therapy
tositumomab
Bexxar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
131I-tositumomab therapy as initial treatment for follicular lymphoma.
BACKGROUND Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy is effective in… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
PURPOSE To determine overall response (OR) and complete response (CR) rates, response duration, progression-free (PFS) and… (More)
Is this relevant?
2005
2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
PURPOSE To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
PURPOSE This study is an integrated efficacy analysis of the five clinical trials of tositumomab and iodine-131 tositumomab in… (More)
Is this relevant?
2005
2005
Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
PURPOSE To determine the maximum outpatient dose of iodine-131 tositumomab (up to 0.75 Gy) combined with high-dose carmustine… (More)
Is this relevant?
2004
2004
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
PURPOSE An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine… (More)
Is this relevant?
2003
2003
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy. The Southwest Oncology Group (SWOG… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2002
2002
Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method.
BACKGROUND A Phase II study of previously untreated patients with malignant low grade follicular lymphoma given a combination of… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
Relapsed B-cell lymphomas are incurable with conventional chemotherapy and radiation therapy, although a fraction of patients can… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
PURPOSE This multicenter phase II study evaluated the efficacy, dosimetry methodology, and safety of iodine-131 tositumomab in… (More)
Is this relevant?